Dabigatran Adherence Pilot Intervention for Patients With Atrial Fibrillation
Atrial Fibrillation
About this trial
This is an interventional health services research trial for Atrial Fibrillation focused on measuring Anti-coagulation
Eligibility Criteria
Inclusion Criteria:
- Patients who have transitioned from warfarin to dabigatran, rivaroxaban, or apixaban or are recently started on anti-coagulation for atrial fibrillation with dabigatran, rivaroxaban, or apixaban will be eligible to be interviewed and partake in the intervention.
- Pharmacists from the Denver VA Medical Center and who work in the anti-coagulation clinics will be eligible to be interviewed.
Exclusion Criteria:
- Patients who prefer a telephone interview but do not have a telephone or cell phone will be excluded.
- Patients for whom the VA is not the primary source of care will also be excluded.
- Pregnant patients will be excluded.
Sites / Locations
- VA Eastern Colorado Health Care System, Denver, CO
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Intervention
Control
Patient education: Patients will receive information on dabigatran, including risks, benefits and potential side effects. This information will be re-enforced during the study on a monthly basis during the IVR calls and during the pharmacy service calls to patients. Tele-monitoring: We will use IVR technology to send patients an automated reminder to refill their dabigatran, rivaroxaban, and apixaban prescriptions. This call will be delivered on day 20 following each dabigatran, rivaroxaban, and apixaban prescription. Pharmacists follow-up: If dabigatran, rivaroxaban, and apixaban has not been refilled, the pharmacy staff will contact the patient to assess reasons that the patient has not refilled the medication.
Usual care